PT  - JOURNAL ARTICLE
AU  - Matthew D. Bucknor
AU  - Daphne Y. Lichtensztajn
AU  - Tracy K. Lin
AU  - Hala T. Borno
AU  - Scarlett L. Gomez
AU  - Thomas A. Hope
TI  - Disparities in PET Imaging for Prostate Cancer at a Tertiary Academic Medical Center
AID  - 10.2967/jnumed.120.251751
DP  - 2021 May 10
TA  - Journal of Nuclear Medicine
PG  - 695--699
VI  - 62
IP  - 5
4099  - http://jnm.snmjournals.org/content/62/5/695.short
4100  - http://jnm.snmjournals.org/content/62/5/695.full
SO  - J Nucl Med2021 May 10; 62
AB  - The purpose of this study was to evaluate differences between patients receiving 18F-fluciclovine and 68Ga-prostate-specific membrane antigen (68Ga-PSMA-11) for biochemically recurrent prostate cancer at a tertiary medical center. Methods: All 18F-fluciclovine and 68Ga-PSMA-11 PET studies performed at the University of California San Francisco from October 2015 to January 2020 were reviewed. Age, race/ethnicity, primary language, body mass index, insurance type, and home address were obtained through the electronic medical record. A logistic regression model was used to evaluate the predictor variables. Results: In total, 1,502 patients received 68Ga-PSMA-11 and 254 patients received 18F-fluciclovine. Black patients had increased odds of receiving imaging with 18F-fluciclovine versus 68Ga-PSMA-11 compared with non-Hispanic White patients (odds ratio, 3.88; 95% CI, 1.90–7.91). There were no other statistically significant differences. Conclusion: In patients receiving molecular imaging for prostate cancer at a single U.S. tertiary medical center, access to 68Ga-PSMA-11 for Black patients was limited, compared with non-Hispanic White patients, by a factor of nearly 4.